Abstract: Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection.

Abstract: Genes associated with schizophrenia are identified. Methods of screening small molecule compounds for use in treating schizophrenia are described.

Abstract: A method of screening a small molecule compound for use in treating Migraine, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by APOE, GNAL, NEDD4L, PDIP, TPCN1, TRPM8, ADRA1B, P2RX4, TAAR2, TAAR3, USP11, CHRNA5, RAB5A, DPP8, F2RL1, FZD5, PTGER1, SPI, ALOX5, CMTM8, DCBLD2, DPYS, IKBKB, OVCH1, PDE4DIP, PPM1G, PYY2, RYR1, BRD2, CAD, F2RL2, NCOA3, ADORA2B, BMX, CHRNA3/CHRNB4, F2R, GRIK5, ITGB4, MAPK10, NPEPL1, PTGIS, UCN2, or WASF1, where activity against said target indicates the test compound has potential use in treating Migraine.

Abstract: A method of screening a small molecule compound for use in treating COPD, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by CELSR3, CHRNA5-THRU-CHRNB4, GPR55, LGR8, PMPCB, SENP1, UCHL1, UQCRC1, BRD2, CCK, HTR6, KCNK3, MBTPS2, NCOA6, PRSS7, SMO, THRA, or NR1D1, where activity against said target indicates the test compound has potential use in treating COPD.

Abstract: A method of screening a small molecule compound for use in treating unipolar depression, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by ADCYAP1R1, HMGB1, MIP, NIPSNAP3A, SRC, WFS1, CLIC6, GABRR3, KDR, PKD1L1, ADARB2, MAP3K1, PPARGC1A, DRD3, PTHR1, BF, CART, CLCN7, EDIL3, GPR73L1, PAQR8, USP2, CCL5, GABBR1, AADACL1, CDK4, DPP4/SLC4A10, FCER2, FZD5, LOC197350, MS4A8B, NOS2A, NTSR1, PSMA4, SREBF1, TAAR2/TAAR3, TLR10, or TPCN1, where activity against said target indicates the test compound has potential use in treating unipolar depression.

Abstract: A method of screening a small molecule compound for use in treating rheumatoid arthritis, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by ACHE, ADAMTS16, AGER, BAT3, BRD2, C2, BF, C4A-THRU-TNXB, C6ORF21, LY6G6D, CACNA1D, CCR4, CLIC1, DNM1, EDG1, FAS, HLA-DQB1, HSPA1L, HTR1B, HTR2B, IL15RA, MICA, NEK2, P2RY10, SEC11L1, SIRT2, NFKBIB, SP1, TPH1, VGF, ATF7, DYRK1B, GABRG3, PTPN22, SEMA4G, TAGLN, PCSK7, TEK, or TRPC6, where activity against said target indicates the test compound has potential use in treating rheumatoid arthritis.

Abstract: A method of screening a small molecule compound for use in treating obesity, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by IRS1, IL12A, ADAMTS7, APG4C, CITED1, GGTLA1, PKD1, TSC2, APG4B, CST7, CXCL5, GPR75, CAPN9, DPYS, F13A1, HFE, GPR173, A2M, CACNG2, KLK7, MAP2K5, PRCP, ABCC3, ADCY9, CHRNA10, ITGA9, CASP1, CLCA2, DKFZP762F0713, ENPEP, FURIN, GPR126, HAT, KCNH2, MAPK4, MIP, MLN, MS4A10, NEFL, SLC6A4, TLR8, or WNT6, where activity against said target indicates the test compound has potential use in treating obesity.

Abstract: A method of screening a small molecule compound for use in treating osteoarthritis, comprising screening a test compound against a target selected from the group consisting of the gene products encoded by ADAM15, ADAM23, ADAM30, C22ORF18, CACNB2, CTRL, LCAT, GPR75, MAOB, OPRL1, GPR8, PKD2L1, PTH, RAB3-GAP150, RARG, SHH, TBXA2R, TNK2, AQP4, CPA1, DPP9, FAM57A, GIPR, HCLS1, FBXO40, NCOA3, NGFB, SERPINA1, or SMAD2, where activity against said target indicates the test compound has potential use in treating osteoarthritis.